Jupiter Neurosciences, Inc. Common Stock (JUNS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.01 (+0.00%), Market cap $0.01B, 52-week low–high $0.20 ~ $2.97.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clin
Financial statements, price targets, institutional (13F) holdings and related news for Jupiter Neurosciences, Inc. Common Stock are updated in real time on BlackAll Trade.
Jupiter Neurosciences, Inc. Common Stock trades at $3.01 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Jupiter Neurosciences, Inc. Common Stock has a market cap of about $0.01B.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the